---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-024005"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:27:32.568705+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IN8bio Phase 1 INB-100: 100% AML remission at median 20.1 months, 100% 1-year PFS/OS

## Summary
- All 9 AML patients remain in complete remission; median follow-up 20.1 months, longest >3 years.
- One-year PFS/OS 100% vs historical controls (CIBMTR PFS 67.8%, OS 74.7%).
- No cytokine release syndrome or neurotoxicity observed; manageable GvHD in line with historical data.
- Patients median age 68, high-risk, including prior CAR-T failures; therapy well-tolerated.
- Company to host conference call today at 8:30am ET to discuss data.

## SEC filing metadata
- accession: 0001193125-25-024005
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312525024005/0001193125-25-024005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312525024005/d905966d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-024005
- JSON: https://secwatch.observer/filing/0001193125-25-024005.json
- Plain text: https://secwatch.observer/filing/0001193125-25-024005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.